BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 08, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/5 cls
Amarin Corp. plc (NASDAQ:AMRN) Wedbush Akiva Felt Downgrade Neutral (from outperform) 0% $12.52
Felt also lowered his target to $15 from $22 on a diminishing probability the company will be acquired. In July, Amarin said it would begin to hire a sales force for Vascepa icosapent ethyl in October if it does not sign a takeover deal. With October underway, Felt said that the "continued absence of a takeover increasingly signals that Amarin lacks the 'must have' status necessary to justify the Street's bullish M&A expectations." In July, FDA approved Vascepa, a purified form of the ethyl ester of eicosapentaenoic acid (ethyl-EPA), as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) BMO Capital Markets Jim Birchenough Price target Outperform 4% $25.16
Jefferies Eun Yang Price target Buy
Summer Street Ling Wang Price target Buy

Read the full 1122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >